PharmaVentures is a dedicated life science focused advisory firm with deep expertise and connectivity across the life sciences spectrum.  Our dedicated advisory team has decades of experience advising clients on successful M&A processes in highly complex transactions.

We use our team’s collective intellectual capital, specialist sector and product expertise, and wealth of experience to deliver the best long-term solutions for our clients. We understand and respect the different requirements of shareholders, management, and other stakeholders. We work closely with our global clients, helping them achieve their strategic objectives and derive optimal value from their M&A transactions.

Our life science clients, including global pharmaceutical companies, biotech companies, diagnostics and healthcare IT companies, healthcare service firms, universities and technology transfer agencies as well underwriters of capital including global PE firms and family offices, have trusted​​ us to support their M&A activities using our:

• extensive sell-side experience that maximises certainty of execution, optimises price, form of consideration and structure in partial or full exits from equity interests and ensures attractive deal terms in competitive processes or bilateral deals;
• specialised buy-side expertise that allows us to position our client favourably vs potential targets and maximises the probability of a successful deal;
• custom made sale process tailored to the situation and needs of our client for equity solutions, products or other assets such as manufacturing sites across a wide range of sub-sectors including pharmaceuticals, medical devices, diagnostics, contract services and imaging systems;
• personal contacts across an extensive network of trade and private equity funds engaged in M&A ensuring that our confidential approach is well-received and placing us in a unique position to support our clients in sell-side or buy-side engagements;
• globally experienced deal making team composed of senior executives from big pharma R&D, BD, management and marketing, complemented by VCs and investment bankers.